CytomX Therapeutics
CTMX
62 hedge funds and large institutions have $308M invested in CytomX Therapeutics in 2016 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 22 increasing their positions, 13 reducing their positions, and 5 closing their positions.
69% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 13
60% more capital invested
Capital invested by funds: $193M → $308M (+$116M)
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
3% more funds holding
Funds holding: 60 → 62 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$12.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$1.41M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.27M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$1.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$7.58M |
| 2 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$2.53M |
| 3 |
CC
Casdin Capital
New York
|
-$1.29M |
| 4 |
EA
Emerald Acquisition
Seattle,
Washington
|
-$264K |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$232K |
CTMX Hedge Fund Activity: Q3 2016 in Review
62 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q3 2016, worth a combined $308M — up 60% from $193M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CTMX positions and 5 closed out — a net gain of 2 holders — while 22 added to existing stakes and 13 trimmed.
The largest buyer was Putnam Investments, adding an estimated $12.6M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $7.58M sold.
- 62 institutional investors held CytomX Therapeutics (CTMX) as of Q3 2016, up from 60 in Q2 2016.
- Funds reported $308M of CytomX Therapeutics stock for Q3 2016, up 60% quarter-over-quarter.
- 7 funds opened new CytomX Therapeutics positions in Q3 2016 and 5 closed out, a net change of +2 holders.
- The largest CytomX Therapeutics buyer in Q3 2016 was Putnam Investments, an estimated $12.6M added.
- The largest CytomX Therapeutics seller in Q3 2016 was Perceptive Advisors, an estimated $7.58M sold.
Based on aggregated 13F filings for Q3 2016.